Lineage Cell Therapeutics, Inc. Equity Method Investment, Realized Gain (Loss) on Disposal
Lineage Cell Therapeutics, Inc. (LCTX) reported Equity Method Investment, Realized Gain (Loss) on Disposal of $8.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-11.
Discontinued › Income Statement › Other Income
us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal · last filed 2021-03-11
- Lineage Cell Therapeutics, Inc. equity method investment, realized gain (loss) on disposal for the quarter ending 2019-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. equity method investment, realized gain (loss) on disposal for the quarter ending 2019-09-30 was -$8.29M.
- Lineage Cell Therapeutics, Inc. equity method investment, realized gain (loss) on disposal for the quarter ending 2019-06-30 was -$21.43M.
- Lineage Cell Therapeutics, Inc. equity method investment, realized gain (loss) on disposal for fiscal 2019 was $8.00M.
| Period end | Equity Method Investment, Realized Gain (Loss) on Disposal 3 month | Equity Method Investment, Realized Gain (Loss) on Disposal 6 month | Equity Method Investment, Realized Gain (Loss) on Disposal 9 month | Equity Method Investment, Realized Gain (Loss) on Disposal 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$8.29M derived: sum of 2 quarters · filed 2021-03-11 | -$29.71M derived: sum of 3 quarters · filed 2021-03-11 | $8.00M 10-K · filed 2021-03-11 |
| 2019-09-30 | -$8.29M 10-Q · filed 2020-11-04 | -$29.71M derived: sum of 2 quarters · filed 2020-11-04 | $8.00M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$21.43M 10-Q · filed 2020-08-06 | $16.29M 10-Q · filed 2020-08-06 | ||
| 2018-06-30 | $3.21M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |